Last reviewed · How we verify

NCT06283316: STA2R

Systemic Treatments for Alopecia Areata Registry

Recruiting now Last updated 28 February 2024
What this trial tests

trial in Alopecia Areata in 10,000 participants. Currently enrolling.

Timeline
17 January 2024
Primary endpoint
31 December 2099
31 December 2099

Quick facts

Lead sponsorErasmus Medical Center
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment10,000
Start date17 January 2024
Primary completion31 December 2099
Estimated completion31 December 2099
Sites1 location across Netherlands

Conditions studied

Sponsor

Erasmus Medical Center

Who can join

16 and older, any sex, with Alopecia Areata or Alopecia Totalis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A multicenter prospective registry (STA2R) is conducted to assess systemic treatments for alopecia areata, focusing on effectiveness, safety, and long-term outcomes.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Alopecia Areata

Currently open trials in the same condition.

Other Erasmus Medical Center trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06283316.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing